164 related articles for article (PubMed ID: 20930614)
1. A robust immunohistochemical assay for detecting PTEN expression in human tumors.
Sangale Z; Prass C; Carlson A; Tikishvili E; Degrado J; Lanchbury J; Stone S
Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):173-83. PubMed ID: 20930614
[TBL] [Abstract][Full Text] [Related]
2. In depth evaluation of the prognostic and predictive utility of PTEN immunohistochemistry in colorectal carcinomas: performance of three antibodies with emphasis on intracellular and intratumoral heterogeneity.
Ágoston EI; Micsik T; Ács B; Fekete K; Hahn O; Baranyai Z; Dede K; Bodoky G; Bursics A; Kulka J; Krenács T; Győrffy B; Harsányi L; Szász AM
Diagn Pathol; 2016 Jul; 11(1):61. PubMed ID: 27392434
[TBL] [Abstract][Full Text] [Related]
3. Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible.
Garg K; Broaddus RR; Soslow RA; Urbauer DL; Levine DA; Djordjevic B
Int J Gynecol Pathol; 2012 Jan; 31(1):48-56. PubMed ID: 22123723
[TBL] [Abstract][Full Text] [Related]
4. Optimal protocol for PTEN immunostaining; role of analytical and preanalytical variables in PTEN staining in normal and neoplastic endometrial, breast, and prostatic tissues.
Maiques O; Santacana M; Valls J; Pallares J; Mirantes C; Gatius S; García Dios DA; Amant F; Pedersen HC; Dolcet X; Matias-Guiu X
Hum Pathol; 2014 Mar; 45(3):522-32. PubMed ID: 24457075
[TBL] [Abstract][Full Text] [Related]
5. An immunohistochemical and fluorescence in situ hybridization-based comparison between the Oracle HER2 Bond Immunohistochemical System, Dako HercepTest, and Vysis PathVysion HER2 FISH using both commercially validated and modified ASCO/CAP and United Kingdom HER2 IHC scoring guidelines.
O'Grady A; Allen D; Happerfield L; Johnson N; Provenzano E; Pinder SE; Tee L; Gu M; Kay EW
Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):489-93. PubMed ID: 20661132
[TBL] [Abstract][Full Text] [Related]
6. Determination of Optimum Formalin Fixation Duration for Prostate Needle Biopsies for Immunohistochemistry and Quantum Dot FISH Analysis.
Sathyanarayana UG; Birch C; Nagle RB; Tomlins SA; Palanisamy N; Zhang W; Hubbard A; Brunhoeber P; Wang Y; Tang L
Appl Immunohistochem Mol Morphol; 2015; 23(5):364-73. PubMed ID: 25265431
[TBL] [Abstract][Full Text] [Related]
7. Expression of PTEN in endometrial liquid-based cytology.
Di Lorito A; Zappacosta R; Capanna S; Gatta DM; Rosini S; Schmitt FC
Acta Cytol; 2014; 58(5):495-500. PubMed ID: 25358681
[TBL] [Abstract][Full Text] [Related]
8. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S
J BUON; 2013; 18(1):44-50. PubMed ID: 23613387
[TBL] [Abstract][Full Text] [Related]
9. Effect of Preanalytic Variables on an Automated PTEN Immunohistochemistry Assay for Prostate Cancer.
Guedes LB; Morais CL; Fedor H; Hicks J; Gurel B; Melamed J; Lee P; Gopalan A; Knudsen BS; True LD; Scher HI; Fine SW; Trock BJ; De Marzo AM; Lotan TL
Arch Pathol Lab Med; 2019 Mar; 143(3):338-348. PubMed ID: 30295067
[TBL] [Abstract][Full Text] [Related]
10. Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry - Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort.
Rulle U; Tsourti Z; Casanova R; Deml KF; Verbeken E; Thunnissen E; Warth A; Cheney R; Sejda A; Speel EJ; Madsen LB; Nonaka D; Navarro A; Sansano I; Marchetti A; Finn SP; Monkhorst K; Kerr KM; Haberecker M; Wu C; Zygoura P; Kammler R; Geiger T; Gendreau S; Schulze K; Vrugt B; Wild P; Moch H; Weder W; Ciftlik AT; Dafni U; Peters S; Bubendorf L; Stahel RA; Soltermann A
J Thorac Oncol; 2018 Dec; 13(12):1851-1863. PubMed ID: 30240851
[TBL] [Abstract][Full Text] [Related]
11. Correlation between NDRG1 and PTEN expression in endometrial carcinoma.
Chen J; Li S; Yang Z; Lu G; Hu H
Cancer Sci; 2008 Apr; 99(4):706-10. PubMed ID: 18377423
[TBL] [Abstract][Full Text] [Related]
12. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
13. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients.
Lotan TL; Gurel B; Sutcliffe S; Esopi D; Liu W; Xu J; Hicks JL; Park BH; Humphreys E; Partin AW; Han M; Netto GJ; Isaacs WB; De Marzo AM
Clin Cancer Res; 2011 Oct; 17(20):6563-73. PubMed ID: 21878536
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry of breast tumor markers on archived bouin-fixed paraffin-embedded tissues.
Gagnon JF; Sanschagrin F; Jacob S; Provencher L; Morin C; Diorio C
Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):168-72. PubMed ID: 20930615
[TBL] [Abstract][Full Text] [Related]
15. PTEN mRNA detection by chromogenic, RNA in situ technologies: a reliable alternative to PTEN immunohistochemistry.
Bingham V; Ong CW; James J; Maxwell P; Waugh D; Salto-Tellez M; McQuaid S
Hum Pathol; 2016 Jan; 47(1):95-103. PubMed ID: 26518664
[TBL] [Abstract][Full Text] [Related]
16. Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma.
Sakr RA; Barbashina V; Morrogh M; Chandarlapaty S; Andrade VP; Arroyo CD; Olvera N; King TA
Appl Immunohistochem Mol Morphol; 2010 Jul; 18(4):371-4. PubMed ID: 20216404
[TBL] [Abstract][Full Text] [Related]
17. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.
Yanagawa N; Leduc C; Kohler D; Saieg MA; John T; Sykes J; Yoshimoto M; Pintilie M; Squire J; Shepherd FA; Tsao MS
J Thorac Oncol; 2012 Oct; 7(10):1513-21. PubMed ID: 22982652
[TBL] [Abstract][Full Text] [Related]
18. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
19. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.
Andersen JN; Sathyanarayanan S; Di Bacco A; Chi A; Zhang T; Chen AH; Dolinski B; Kraus M; Roberts B; Arthur W; Klinghoffer RA; Gargano D; Li L; Feldman I; Lynch B; Rush J; Hendrickson RC; Blume-Jensen P; Paweletz CP
Sci Transl Med; 2010 Aug; 2(43):43ra55. PubMed ID: 20686178
[TBL] [Abstract][Full Text] [Related]
20. E- to N-cadherin switch in melanoma is associated with decreased expression of phosphatase and tensin homolog and cancer progression.
Lade-Keller J; Riber-Hansen R; Guldberg P; Schmidt H; Hamilton-Dutoit SJ; Steiniche T
Br J Dermatol; 2013 Sep; 169(3):618-28. PubMed ID: 23662813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
